{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:46:58Z","timestamp":1784630818212,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.yebeh.2007.09.023","type":"journal-article","created":{"date-parts":[[2008,1,7]],"date-time":"2008-01-07T07:55:52Z","timestamp":1199692552000},"page":"49-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Effect of the new antiepileptic drug retigabine in a rodent model of mania"],"prefix":"10.1016","volume":"12","author":[{"given":"Ditte","family":"Dencker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Lund","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Husum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2007.09.023_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1001\/archneur.60.4.496","article-title":"M-channels: neurological diseases, neuromodulation, and drug development","volume":"60","author":"Cooper","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2007.09.023_bib2","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1523\/JNEUROSCI.23-18-07227.2003","article-title":"KCNQ\/M currents in sensory neurons: significance for pain therapy","volume":"23","author":"Passmore","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2007.09.023_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0306-4522(03)00321-X","article-title":"Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation","volume":"120","author":"Yus-Najera","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.yebeh.2007.09.023_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/35036198","article-title":"Neuronal KCNQ potassium channels: physiology and role in disease","volume":"1","author":"Jentsch","year":"2000","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.yebeh.2007.09.023_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0026-895X(24)12060-3","article-title":"Modulation of KCNQ2\/3 potassium channels by the novel anticonvulsant retigabine","volume":"58","author":"Main","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.yebeh.2007.09.023_bib6","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001","article-title":"Activation of expressed KCNQ potassium currents and native neuronal m-type potassium currents by the anticonvulsant drug retigabine","volume":"21","author":"Tatulian","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2007.09.023_bib7","doi-asserted-by":"crossref","unstructured":"Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 279:403\u20136.","DOI":"10.1126\/science.279.5349.403"},{"key":"10.1016\/j.yebeh.2007.09.023_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3458.2005.tb00033.x","article-title":"Retigabine: chemical synthesis to clinical application","volume":"11","author":"Blackburn-Munro","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.yebeh.2007.09.023_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.tpj.6500400","article-title":"PP2A-Bgamma subunit and KCNQ2 K+ channels in bipolar disorder","volume":"7","author":"Borsotto","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.yebeh.2007.09.023_bib10","series-title":"Diagnostic and statistical manual of mental disorders\u2014fourth edition (DMS-IV)","author":"Rush","year":"2000"},{"key":"10.1016\/j.yebeh.2007.09.023_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269881103017002003","article-title":"Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology","volume":"17","author":"Goodwin","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.yebeh.2007.09.023_bib12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2165\/00023210-200620070-00005","article-title":"Retigabine: in partial seizures","volume":"20","author":"Plosker","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2007.09.023_bib13","doi-asserted-by":"crossref","unstructured":"Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4:149\u201354.","DOI":"10.1016\/j.nurt.2006.11.012"},{"key":"10.1016\/j.yebeh.2007.09.023_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10519-006-9093-4","article-title":"Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease","volume":"37","author":"Einat","year":"2007","journal-title":"Behav Genet"},{"key":"10.1016\/j.yebeh.2007.09.023_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pnpbp.2003.10.015","article-title":"Perspectives for the development of animal models of bipolar disorder","volume":"28","author":"Machado-Vieira","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2007.09.023_bib16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF00217062","article-title":"Hyperactivity induced by dexamphetamine\/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?","volume":"91","author":"Aylmer","year":"1987","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.yebeh.2007.09.023_bib17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/2111312a0","article-title":"Combined effects of chlordiazepoxide and dexamphetamine on activity of rats in an unfamiliar environment","volume":"211","author":"Rushton","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.yebeh.2007.09.023_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1006\/ebeh.2001.0254","article-title":"Effect of the new antiepileptic drug levetiracetam in an animal model of mania","volume":"2","author":"Lamberty","year":"2001","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2007.09.023_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-2999(93)90266-K","article-title":"Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents","volume":"237","author":"Cao","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2007.09.023_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/BF00518190","article-title":"Effect of lithium administration on rat brain 5-hydroxyindole levels in a possible animal model for mania","volume":"91","author":"Vale","year":"1987","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.yebeh.2007.09.023_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbr.2004.08.015","article-title":"Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania","volume":"158","author":"Arban","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.yebeh.2007.09.023_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.64719\/pb.4195","article-title":"New approaches to modeling bipolar disorder","volume":"37","author":"Einat","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.yebeh.2007.09.023_bib23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0028-3908(02)00237-X","article-title":"Potassium channels as anti-epileptic drug targets","volume":"43","author":"Wickenden","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2007.09.023_bib24","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1124\/mol.104.010793","article-title":"The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate","volume":"67","author":"Wuttke","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.yebeh.2007.09.023_bib25","first-page":"1063","article-title":"Investigations into the mechanism of action of the new anticonvulsant retigabine: interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels","volume":"50","author":"Rundfeldt","year":"2000","journal-title":"Arzneimittelforschung"},{"issue":"Suppl. 3","key":"10.1016\/j.yebeh.2007.09.023_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1590\/S1516-44462004000700005","article-title":"Physiopathology of bipolar disorders: what have changed in the last 10 years?","volume":"26","author":"Kapczinski","year":"2004","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.yebeh.2007.09.023_bib27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1146\/annurev.pa.33.040193.003231","article-title":"Amphetamine: effects on catecholamine systems and behavior","volume":"33","author":"Seiden","year":"1993","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.yebeh.2007.09.023_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neulet.2004.03.025","article-title":"The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat","volume":"362","author":"Mikkelsen","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.yebeh.2007.09.023_bib29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1124\/jpet.106.106757","article-title":"The KCNQ opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat","volume":"318","author":"Hansen","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2007.09.023_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/01.jcp.0000236661.95200.3e","article-title":"An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients","volume":"26","author":"Amann","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2007.09.023_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000026528","article-title":"Modulation of calcium and potassium currents by lamotrigine","volume":"38","author":"Grunze","year":"1998","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.yebeh.2007.09.023_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF01958152","article-title":"4-Aminopyridine and barium chloride attenuate the anti-epileptic effect of carbamazepine in hippocampal slices","volume":"47","author":"Olpe","year":"1991","journal-title":"Experientia"},{"key":"10.1016\/j.yebeh.2007.09.023_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0924-977X(93)90265-N","article-title":"Effects of valproate on early and late potassium currents of single neurons","volume":"3","author":"Walden","year":"1993","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505007003290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505007003290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:20:42Z","timestamp":1761502842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505007003290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S1525505007003290"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2007.09.023","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the new antiepileptic drug retigabine in a rodent model of mania","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2007.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}